Leonid Timashev
Stock Analyst at RBC Capital
(3.57)
# 809
Out of 5,179 analysts
162
Total ratings
43.75%
Success rate
6.65%
Average return
Main Sectors:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCYC Bicycle Therapeutics | Maintains: Sector Perform | $11 → $7 | $4.31 | +62.41% | 3 | Mar 18, 2026 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $18 → $14 | $4.07 | +243.98% | 2 | Mar 17, 2026 | |
| LEGN Legend Biotech | Maintains: Outperform | $66 → $62 | $16.80 | +269.05% | 16 | Mar 11, 2026 | |
| DSGN Design Therapeutics | Maintains: Outperform | $13 → $14 | $10.54 | +32.83% | 11 | Mar 10, 2026 | |
| NUVB Nuvation Bio | Maintains: Outperform | $12 → $13 | $4.25 | +205.88% | 5 | Mar 3, 2026 | |
| BHVN Biohaven | Maintains: Outperform | $22 → $23 | $8.37 | +174.79% | 15 | Mar 3, 2026 | |
| EXEL Exelixis | Maintains: Sector Perform | $46 → $43 | $41.53 | +3.54% | 4 | Mar 2, 2026 | |
| ONC BeOne Medicines AG | Maintains: Outperform | $417 → $425 | $283.03 | +50.16% | 6 | Feb 27, 2026 | |
| ALKS Alkermes | Maintains: Outperform | $47 → $45 | $29.39 | +53.11% | 6 | Feb 26, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $191 → $195 | $182.69 | +6.74% | 4 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $219 → $222 | $156.35 | +41.99% | 16 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $95 → $101 | $62.50 | +61.60% | 7 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $49 | $30.46 | +60.87% | 5 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $5.37 | +309.68% | 6 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $61 → $73 | $64.62 | +12.97% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $44 → $47 | $29.98 | +56.77% | 9 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $13 | $6.71 | +93.74% | 3 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $77 → $140 | $92.51 | +51.33% | 2 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $197 → $200 | $145.30 | +37.65% | 8 | Jan 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $1.31 | +281.68% | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $5 → $4 | $1.05 | +280.95% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $49 → $50 | $30.84 | +62.13% | 15 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $19 | $11.42 | +66.37% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $13 | $5.04 | +157.94% | 2 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $5 | $3.70 | +35.14% | 1 | Jun 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $0.75 | +301.39% | 1 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $70 | $90.30 | -22.48% | 1 | Jan 23, 2025 |
Bicycle Therapeutics
Mar 18, 2026
Maintains: Sector Perform
Price Target: $11 → $7
Current: $4.31
Upside: +62.41%
Perspective Therapeutics
Mar 17, 2026
Maintains: Outperform
Price Target: $18 → $14
Current: $4.07
Upside: +243.98%
Legend Biotech
Mar 11, 2026
Maintains: Outperform
Price Target: $66 → $62
Current: $16.80
Upside: +269.05%
Design Therapeutics
Mar 10, 2026
Maintains: Outperform
Price Target: $13 → $14
Current: $10.54
Upside: +32.83%
Nuvation Bio
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $4.25
Upside: +205.88%
Biohaven
Mar 3, 2026
Maintains: Outperform
Price Target: $22 → $23
Current: $8.37
Upside: +174.79%
Exelixis
Mar 2, 2026
Maintains: Sector Perform
Price Target: $46 → $43
Current: $41.53
Upside: +3.54%
BeOne Medicines AG
Feb 27, 2026
Maintains: Outperform
Price Target: $417 → $425
Current: $283.03
Upside: +50.16%
Alkermes
Feb 26, 2026
Maintains: Outperform
Price Target: $47 → $45
Current: $29.39
Upside: +53.11%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $191 → $195
Current: $182.69
Upside: +6.74%
Feb 24, 2026
Maintains: Outperform
Price Target: $219 → $222
Current: $156.35
Upside: +41.99%
Feb 20, 2026
Maintains: Outperform
Price Target: $95 → $101
Current: $62.50
Upside: +61.60%
Feb 18, 2026
Reiterates: Outperform
Price Target: $49
Current: $30.46
Upside: +60.87%
Feb 18, 2026
Maintains: Outperform
Price Target: $21 → $22
Current: $5.37
Upside: +309.68%
Jan 21, 2026
Maintains: Outperform
Price Target: $61 → $73
Current: $64.62
Upside: +12.97%
Jan 21, 2026
Maintains: Outperform
Price Target: $44 → $47
Current: $29.98
Upside: +56.77%
Jan 21, 2026
Maintains: Outperform
Price Target: $22 → $13
Current: $6.71
Upside: +93.74%
Jan 21, 2026
Maintains: Outperform
Price Target: $77 → $140
Current: $92.51
Upside: +51.33%
Jan 21, 2026
Maintains: Outperform
Price Target: $197 → $200
Current: $145.30
Upside: +37.65%
Dec 19, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $1.31
Upside: +281.68%
Nov 11, 2025
Maintains: Sector Perform
Price Target: $5 → $4
Current: $1.05
Upside: +280.95%
Nov 7, 2025
Maintains: Outperform
Price Target: $49 → $50
Current: $30.84
Upside: +62.13%
Nov 6, 2025
Maintains: Outperform
Price Target: $18 → $19
Current: $11.42
Upside: +66.37%
Aug 8, 2025
Maintains: Outperform
Price Target: $12 → $13
Current: $5.04
Upside: +157.94%
Jun 20, 2025
Maintains: Outperform
Price Target: $8 → $5
Current: $3.70
Upside: +35.14%
Mar 19, 2025
Maintains: Buy
Price Target: $3
Current: $0.75
Upside: +301.39%
Jan 23, 2025
Reiterates: Sector Perform
Price Target: $70
Current: $90.30
Upside: -22.48%